Windtree Therapeutics (NASDAQ: WINT) and Epirus Biopharmaceuticals (NASDAQ:EPRS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitabiliy, valuation, institutional ownership, earnings and analyst recommendations.

Valuation & Earnings

This table compares Windtree Therapeutics and Epirus Biopharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Windtree Therapeutics $2.19 million 1.23 -$31.78 million ($5.25) -0.05
Epirus Biopharmaceuticals N/A N/A N/A ($2.53) -0.06

Epirus Biopharmaceuticals has higher revenue, but lower earnings than Windtree Therapeutics. Epirus Biopharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

36.8% of Windtree Therapeutics shares are owned by institutional investors. 1.3% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Windtree Therapeutics and Epirus Biopharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -3,983.56% N/A -326.94%
Epirus Biopharmaceuticals -2,025.65% -208.66% -97.67%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Windtree Therapeutics and Epirus Biopharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 1 0 2.50
Epirus Biopharmaceuticals 0 0 0 0 N/A

Windtree Therapeutics presently has a consensus price target of $8.00, indicating a potential upside of 2,707.02%. Given Windtree Therapeutics’ higher probable upside, equities analysts plainly believe Windtree Therapeutics is more favorable than Epirus Biopharmaceuticals.

Volatility & Risk

Windtree Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, Epirus Biopharmaceuticals has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500.

Summary

Windtree Therapeutics beats Epirus Biopharmaceuticals on 6 of the 10 factors compared between the two stocks.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Epirus Biopharmaceuticals Company Profile

EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company’s products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

Receive News & Ratings for Windtree Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.